AzTrials
AzTrials

Alcohol DependanceEarly Phase 1ARC4NCT02939313

Cortical rTMS as a Tool to Change Brain Reactivity to Alcohol Cues

A Early Phase 1 study testing medial prefrontal cortex and dorsolateral prefrontal cortex in people with Alcohol Dependance, run by Medical University of South Carolina at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this investigation is to determine if, in heavy alcohol users, a single session of transcranial magnetic brain stimulation (TMS) over a brain region involved in craving (medial prefrontal cortex) and a brain region involved in cogntive control (dorsolateral prefrontal cortex) can lower an individual's… Read more about this study

Who is it for?
Ages 21 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Alcohol Dependance
What is being tested?
medial prefrontal cortex and dorsolateral prefrontal cortex
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
71 participants
Where
1 siteUnited States
Study dates
Jan 2016to 12 Apr 2021
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Inclusion Criteria: Age 21-40; Current alcohol use greater than 20 standard drinks per week; Current DSM-5 Alcohol Use Disorder diagnosis, including the loss of control item; Currently not engaged in, and do not want treatment for, alcohol related problems; Able to read and understand questionnaires and informed consent; Lives within 50 miles of the study site. Exclusion Criteria: [These are listed in greater detail in the CIA Core] Any current DSM-5 Axis I diagnosis except Alcohol or Nicotine Use Disorder; Current use of any psychoactive substance except nicotine and marijuana or medication as evidenced by self-report or urine drug screen; History of head trauma or epilepsy; Current suicidal or homicidal ideation; Presence of ferrous metal in the body, as evidenced by metal screening and self-report; Severe claustrophobia or extreme obesity that preclude placement in the MRI scanner. For female participants, pregnancy, as evidenced by a urine pregnancy test administered on the day of the scanning session.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Medical University of South Carolina

    Charleston, South Carolina, 29425

Other trials in United States

About this study

Official title: Charleston ARC Clinical Project 4 Cortical rTMS as a Tool to Change Craving and Brain Reactivity to Alcohol Cues

The goal of this investigation is to determine if, in heavy alcohol users, a single session of transcranial magnetic brain stimulation (TMS) over a brain region involved in craving (medial prefrontal cortex) and a brain region involved in cogntive control (dorsolateral prefrontal cortex) can lower an individual's craving and brain response to alcohol cues. This study involves a screening visit, followed by three visits which involve brain imaging (using functional MRI) and brain stimulation (using TMS). There is also an additional Magnetic resonance spectroscopy (MRS) exploratory Aim in which we will measure the concentration of glutamate in the prefrontal cortex before and after a session of TMS.

Read the detailed description

Alcohol Use Disorders (AUDs) are prevalent, devastating, and difficult to treat. High relapse rates are likely due to factors that affect limbic and executive circuits in the brain, including vulnerability to salient cues and loss of cognitive control. Limbic drive and executive control are regulated by two cortical-subcortical neural circuits -the limbic loop that includes projections from the medial prefrontal cortex (mPFC) to the ventral striatum, and the executive control loop that includes projections from the dorsolateral prefrontal cortex (dlPFC) to the dorsal striatum. Optogenetic manipulation in animals has demonstrated a causal relationship between activity in these frontal-striatal circuits and drinking behavior. Consequently, an innovative and potentially fruitful new strategy in the treatment of AUDs in humans would be to selectively attenuate limbic circuitry (to reduce reward salience), and/or amplify executive circuitry, through targeted brain stimulation. Previous studies have demonstrated that a single session of 10 Hz transcranial magnetic stimulation (TMS) over the dlPFC can lead to a decrease in craving for alcohol, nicotine, and cocaine. Our laboratory has demonstrated that a single session of continuous theta burst (cTBS) TMS over the mPFC can also decrease craving, as well as the brain response to drug cues in cocaine users (Hanlon et al, in review) and alcohol users (see Significance). The overarching goal of this proposal is to determine which of these two TMS strategies - amplifying dlPFC activity or inhibiting mPFC activity - is more efficacious in decreasing alcohol craving and the brain response to cues. This will provide an evidence-based foundation for cortical target selection in future TMS clinical trials - an innovative treatment strategy for AUD patients.

As a recent FDA-approved treatment for depression, there is a growing interest in investigating TMS as a treatment for drug and alcohol use disorders. By changing the frequency and pattern of stimulation, it is possible to induce a long-term potentiation (LTP) or long-term depression (LTD) of activity in the cortical area stimulated as well in its monosynaptic targets. To date, nearly all published reports of brain stimulation as a tool for decreasing craving have focused on applying LTP-like stimulation (typically 10 Hz) to the dlPFC, thereby strengthening executive control circuitry. An alternative approach is to apply LTD-like TMS (such as cTBS) to the mPFC, thereby weakening limbic drive circuitry (which is engaged during craving). A sham TMS-controlled crossover study of 12 heavy alcohol users in our lab indicated that a single dose of mPFC cTBS decreases self-reported craving and the BOLD response to alcohol cues in the mPFC and striatum (limbic regions involved in craving). Using MR spectroscopy, we further demonstrated that cTBS-reduced the glutamine concentration in the mPFC, which may be related to the decrease in BOLD signal and functional connectivity with this region. Before moving forward with large and expensive multisite clinical trials, it is important to determine which cortical target (mPFC vs dlPFC) is likely to have a greater effect on the brain response to alcohol cues (Aim 1), and which will have a greater effect on self-reported craving (Aim 2) -a major factor contributing to relapse and sustained heavy drinking among individuals with AUDs. In this three-visit crossover design, a cohort of non-treatment seeking AUD individuals will receive sham, mPFC, or dlPFC TMS at each visit followed by alcohol-cue induced BOLD imaging and MR Spectroscopy. We will determine whether LTD-like mPFC TMS is more effective than LTP-like dlPFC TMS in:

Aim 1: Reducing alcohol cue-elicited brain activity in limbic circuitry. Participants will be exposed to our well-established fMRI alcohol cue paradigm. We will measure the percent BOLD signal change within a network of limbic regions typically activated by alcohol cues (e.g. mPFC, ACC, striatum) (Schacht et al., 2014), as well as functional connectivity between these regions (using psychophysiologic interactions). We will test the hypotheses that 1) both LTD-like stimulation to the mPFC (via cTBS) and LTP-like stimulation to the dlPFC (via 10Hz TMS) will significantly decrease alcohol cue-induced activation of limbic circuitry compared to sham stimulation and 2) this attenuating effect will be more robust when stimulation is targeted at the mPFC directly with cTBS stimulation (rather than indirectly via 10 Hz dlPFC stimulation).

Aim 2: Reducing self-reported alcohol craving. Using intermittent self-reported assessments of the desire to drink alcohol throughout the experimental sessions (before, during, and at several time points after the TMS treatment), we will test the hypothesis that LTD-like stimulation to the mPFC (via cTBS) will decrease self-reported alcohol craving more than will LTP-like stimulation to the dlPFC (via 10Hz TMS).

Finally, to develop a comprehensive and evidence-based foundation for future clinical trials, we will also explore the effects of these innovative brain stimulation treatment strategies on neurochemistry:

Exploratory Aim 3: Regional neurochemistry. Through MR Spectroscopy, we will test the hypothesis that the effects of TMS on the outcomes of Aim 1 \& 2 are mediated by changes in mPFC excitatory/inhibitory neurochemical balance (i.e., changes in glutamate, glutamine, GABA concentrations).

Being tested
medial prefrontal cortex, dorsolateral prefrontal cortex, sham
Keywords
alcohol, addiction, cTBS
Medical subject headings
Behavior, Addictive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • medial prefrontal cortexDevice

    Also called medial prefrontal

    a form of theta burst stimulation that noninvasively induces a depression in brain reactivity

  • dorsolateral prefrontal cortexDevice

    Also called dorsolateral prefrontal

    a form of transcranial magnetic stimulation that noninvasively induces an increase in brain reactivity

  • shamDevice

    sham stimulation

Study groups in NCT02939313
Study groupRoleWhat they receive
medial prefrontalExperimentalIndividuals will receive medial prefrontal cortex stimulation
Receives: Device: medial prefrontal cortex
dorsolateral prefrontalExperimentalIndividuals will receive dorsolateral prefrontal cortex stimulation
Receives: Device: dorsolateral prefrontal cortex
shamSham comparatorIndividuals will receive sham stimulation to the medial prefrontal and dorsolateral prefrontal cortex
Receives: Device: sham

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percent signal change in the MPFC

    Measured: immediately after the treatment

  2. Percent signal change in the DLPFC

    Measured: immediately after the treatment

  3. Change in craving score

    Measured: immediately after the treatment

Secondary outcomes (2)
  1. Change in glutmate concentration

    Measured: immediately after the treatment

  2. Change in GABA concentration

    Measured: immediately after the treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Oct 2016 (estimated)
  2. Study startJan 2016
  3. Primary completion12 Apr 2021
  4. Study completion12 Apr 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
71 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02939313
Sponsor's protocol ID
00050256
Other IDs
P50AA010761
Acronym
ARC4
Status last verified
Jan 2022
First submitted
1 Sep 2016
Last updated
13 Jan 2022
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Yes: Data will be shared with the National Institute of Health Neuroimaging Biorepository at the completion of the study

Publications

  • Sinha R. New findings on biological factors predicting addiction relapse vulnerability. Curr Psychiatry Rep. 2011 Oct;13(5):398-405. doi: 10.1007/s11920-011-0224-0.

    PubMed 21792580
  • Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005 Aug;162(8):1403-13. doi: 10.1176/appi.ajp.162.8.1403.

    PubMed 16055761
  • Sinha R, Catapano D, O'Malley S. Stress-induced craving and stress response in cocaine dependent individuals. Psychopharmacology (Berl). 1999 Mar;142(4):343-51. doi: 10.1007/s002130050898.

    PubMed 10229058
  • Lee JL, Milton AL, Everitt BJ. Cue-induced cocaine seeking and relapse are reduced by disruption of drug memory reconsolidation. J Neurosci. 2006 May 31;26(22):5881-7. doi: 10.1523/JNEUROSCI.0323-06.2006.

    PubMed 16738229
  • Volkow ND, Wang GJ, Fowler JS, Tomasi D. Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol. 2012;52:321-36. doi: 10.1146/annurev-pharmtox-010611-134625. Epub 2011 Sep 27.

    PubMed 21961707
  • Bolla K, Ernst M, Kiehl K, Mouratidis M, Eldreth D, Contoreggi C, Matochik J, Kurian V, Cadet J, Kimes A, Funderburk F, London E. Prefrontal cortical dysfunction in abstinent cocaine abusers. J Neuropsychiatry Clin Neurosci. 2004 Fall;16(4):456-64. doi: 10.1176/jnp.16.4.456.

    PubMed 15616172
  • Bolla KI, Eldreth DA, London ED, Kiehl KA, Mouratidis M, Contoreggi C, Matochik JA, Kurian V, Cadet JL, Kimes AS, Funderburk FR, Ernst M. Orbitofrontal cortex dysfunction in abstinent cocaine abusers performing a decision-making task. Neuroimage. 2003 Jul;19(3):1085-94. doi: 10.1016/s1053-8119(03)00113-7.

    PubMed 12880834
  • Hanlon CA, Wesley MJ, Stapleton JR, Laurienti PJ, Porrino LJ. The association between frontal-striatal connectivity and sensorimotor control in cocaine users. Drug Alcohol Depend. 2011 Jun 1;115(3):240-3. doi: 10.1016/j.drugalcdep.2010.11.008. Epub 2010 Dec 28.

    PubMed 21193273
  • Gu H, Salmeron BJ, Ross TJ, Geng X, Zhan W, Stein EA, Yang Y. Mesocorticolimbic circuits are impaired in chronic cocaine users as demonstrated by resting-state functional connectivity. Neuroimage. 2010 Nov 1;53(2):593-601. doi: 10.1016/j.neuroimage.2010.06.066. Epub 2010 Jul 11.

    PubMed 20603217
  • Bear MF, Malenka RC. Synaptic plasticity: LTP and LTD. Curr Opin Neurobiol. 1994 Jun;4(3):389-99. doi: 10.1016/0959-4388(94)90101-5.

    PubMed 7919934
  • Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron. 2004 Sep 30;44(1):5-21. doi: 10.1016/j.neuron.2004.09.012.

    PubMed 15450156
  • Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta burst stimulation of the human motor cortex. Neuron. 2005 Jan 20;45(2):201-6. doi: 10.1016/j.neuron.2004.12.033.

    PubMed 15664172
  • Di Lazzaro V, Pilato F, Saturno E, Oliviero A, Dileone M, Mazzone P, Insola A, Tonali PA, Ranieri F, Huang YZ, Rothwell JC. Theta-burst repetitive transcranial magnetic stimulation suppresses specific excitatory circuits in the human motor cortex. J Physiol. 2005 Jun 15;565(Pt 3):945-50. doi: 10.1113/jphysiol.2005.087288. Epub 2005 Apr 21.

    PubMed 15845575
  • Verbruggen F, Aron AR, Stevens MA, Chambers CD. Theta burst stimulation dissociates attention and action updating in human inferior frontal cortex. Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13966-71. doi: 10.1073/pnas.1001957107. Epub 2010 Jul 14.

    PubMed 20631303
  • Cho SS, Ko JH, Pellecchia G, Van Eimeren T, Cilia R, Strafella AP. Continuous theta burst stimulation of right dorsolateral prefrontal cortex induces changes in impulsivity level. Brain Stimul. 2010 Jul;3(3):170-6. doi: 10.1016/j.brs.2009.10.002. Epub 2009 Oct 31.

    PubMed 20633446

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing medial prefrontal cortex and dorsolateral prefrontal cortex in people with Alcohol Dependance, run by Medical University of South Carolina at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Jan 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percent signal change in the MPFC (time frame: immediately after the treatment). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02939313, which also lists 28 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in